InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,486.00
(
-0.26%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.40
(
-0.61%
)
Bitcoin
69,241.22
(
-2.17%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119787
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: gym gravity post# 11591

Monday, 06/09/2008 9:45:54 PM

Monday, June 09, 2008 9:45:54 PM

Post# of 19309
Re: Thrombate (plasma-derived AT) production plans

Following is an excerpt from the mid-2007 SEC papers filed by Talecris to
support an IPO. (As LRG pointed out, the IPO plans have been rescinded.)

http://www.sec.gov/Archives/edgar/data/1405197/000104746907005901/a2178655zs-1.htm [page 113, emphasis added]

>>
…we are working to transfer production of our product Thrombate III Antithrombin III from Bayer, with whom we have a supply agreement through 2008, with an option to extend through 2009. We anticipate shifting production of Thrombate III Antithrombin III to our facilities by 2011, which we expect will allow for further volume increases. We are continuing to assess Thrombate III Antithrombin III for potential therapies in the areas of cardiovascular, transplant, and sepsis.
<<

In other words, Talecris won’t be able to materially expand production of Thrombate for a few years. Obviously, this is good for GTC and its US partner.

p.s. Interesting that the above excerpt mentions sepsis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up